Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,406 across all filing types
Latest filing 2019-12-13 Regulatory Filings
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma Provides Update on Lacutamab Tellomak Trial
Regulatory Filings Classification · 91% confidence The document is a press release dated December 13, 2019, providing an update on the TELLOMAK Phase II clinical trial for lacutamab. It discusses operational decisions (pausing enrollment, continuing treatment) based on feedback from regulatory authorities concerning a manufacturing quality issue (CMC process) involving a subcontractor (RFS) who filed for bankruptcy and withdrew a Certificate of Conformity. This content details specific operational and regulatory interactions concerning a drug trial, rather than presenting full periodic financial results (like 10-K or IR), management changes (MANG), or formal voting results (DVA). It is an announcement regarding a significant development impacting clinical operations and regulatory compliance. While it touches upon regulatory feedback, it is not a formal regulatory filing itself, nor is it a general earnings release. It is best classified as a Legal Proceedings Report (LTR) because it details issues arising from a manufacturing/quality failure that has triggered regulatory scrutiny and potential legal/operational consequences, or potentially a Regulatory Filing (RNS) as a general announcement of material information. Given the focus on regulatory feedback, manufacturing quality issues, and the impact on a clinical trial, LTR is a strong candidate, but since it is a proactive update on a quality/regulatory matter rather than a lawsuit, RNS (General Regulatory Announcement/Fallback) is often used for such specific operational updates that don't fit other categories. However, since it directly addresses issues with regulatory agencies and manufacturing quality that could lead to legal/compliance issues, LTR is plausible. Reviewing the definitions, LTR is for 'significant lawsuits, regulatory actions, or legal matters'. This is a regulatory action/feedback loop. If it were purely about financial results or strategy, IP or ER would fit. Since it is a specific operational/regulatory update that doesn't fit the core definitions of ER, IR, 10-K, or CT, RNS is the safest fallback. However, the core issue is a quality failure leading to regulatory intervention, which often falls under LTR or RNS. Given the nature of the announcement (update on trial status due to regulatory/quality feedback), it is a material event announcement. I will classify it as RNS as it is a general regulatory announcement that doesn't fit the more specific operational/financial categories, adhering to the principle that specific operational updates often default to RNS if LTR (lawsuits) or other categories don't perfectly align.
2019-12-13 English
FORM 6-K
Foreign Filer Report
2019-12-09 English
Innate Pharma présente Lumoxiti®, médicament approuvé par la FDA, au congrès de l'ASH 2019
Earnings Release Classification · 95% confidence The document is a press release dated December 8, 2019, announcing that Innate Pharma presented new long-term data for its drug Lumoxiti at the 61st American Society of Hematology (ASH) Annual Meeting. It details clinical trial results (Phase III '1053' study), efficacy data, safety profiles, and provides background information on the drug and the company. This format—a formal announcement of scientific/clinical data presentation, often including tables and quotes from management/investigators—is characteristic of an Earnings Release (ER) or a general press release related to operational/scientific updates. Since it focuses on presenting key results from a clinical trial and conference presentation, it aligns best with the 'Earnings Release' (ER) category, which often covers key periodic results, even if the results are scientific rather than purely financial performance metrics. It is not a full Annual Report (10-K), a formal Audit Report (AR), or a transcript (CT). Given the context of presenting new data/results, ER is the most appropriate fit among the options provided for a company update. FY 2019
2019-12-08 French
Innate Pharma highlights FDA-approved Lumoxiti® at ASH 2019
Regulatory Filings Classification · 99% confidence The document is a press release dated December 8, 2019, detailing new, long-term efficacy data from a Phase III clinical trial ('1053') for the drug Lumoxiti, presented at the ASH 2019 meeting. It includes detailed efficacy tables, safety profiles, and background information on the drug and the company (Innate Pharma). This content structure—announcing clinical data presentation at a major conference—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical updates, rather than a formal regulatory filing like a 10-K, IR, or a specific financial report. Since it focuses on clinical trial results and company highlights, it aligns best with the 'Earnings Release' category, which often encompasses major operational news releases, especially when financial results are not the primary focus, or it could be classified as a general Regulatory Filing (RNS) if ER is too narrow. However, given the structure of presenting key data points and commentary following a major event (ASH presentation), ER is a strong fit for a major corporate announcement. Since the document is a detailed press release announcing clinical data, and not a formal financial report, ER is the most appropriate classification among the options provided for a major corporate update.
2019-12-08 English
FORM 6-K
Foreign Filer Report
2019-12-06 English
INNATE PHARMA RELEASES ITS FINANCIAL CALENDAR FOR 2020
Report Publication Announcement Classification · 85% confidence The document is titled "INNATE PHARMA RELEASES ITS FINANCIAL CALENDAR FOR 2020" and explicitly lists future dates for key corporate events, including the 'Publication of 2019 financial statements', 'Publication of revenue for 1Q2020', and the 'Annual General Shareholders Meeting'. This document is an announcement detailing the schedule of future corporate reports and meetings, rather than the reports themselves (like 10-K, ER, or IR). Since it announces the schedule for future corporate events and report publications, it fits best under the category of a general announcement regarding corporate activities or future reporting schedules. While it mentions the AGM date, the primary purpose is the entire calendar release. Given the options, this is a general corporate announcement about future reporting events. It is not a specific report (like 10-K, ER, IR) nor is it a specific announcement about a dividend (DIV) or management change (MANG). It is closest to a Report Publication Announcement (RPA) in spirit, as it announces *when* reports will be published, but RPA is usually for announcing the publication of an *attached* report. Since this is a forward-looking calendar, and it doesn't fit any other specific category (like DIRS, CAP, CT), the most appropriate fallback for a general corporate schedule announcement that doesn't fit elsewhere is Regulatory Filings (RNS), or potentially a general Investor Relations document. However, since it is announcing the schedule for future reports and the AGM, and it is a press release format, it is a general corporate communication. Given the strict definitions, and noting that it announces the date of the AGM, it is a corporate communication about future events. I will classify this as a Report Publication Announcement (RPA) because it is announcing the publication schedule for future financial reports, which is a common function of an RPA, even if the reports aren't attached here. If RPA is too specific, RNS is the fallback. Given the content focuses heavily on *when* financial statements and revenue will be published, RPA seems slightly more descriptive than the general RNS.
2019-12-04 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.